Akero Therapeutics, Inc.
AKRONASDAQHealthcare
$54.65
+$0.00(+0.00%)
Market Cap$4.5B
P/E Ratio—
52W High$58.4
52W Low$21.34
Akero Therapeutics, Inc. (AKRO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AKRO · earnings · updated Jun 8, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 7, 2025EPS Actual
-$0.99
Est. -$0.94 · -5.3%
Revenue
—
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 7, 2025
After Market Close
▼ Miss EPS
AKRO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q4 FY2025 | Nov 7, 2025 | -$0.94 | -$0.99 | -5.3% | — | — | — |
| ▲ Q3 FY2025 | Aug 8, 2025 | -$0.97 | -$0.86 | +11.3% | — | — | — |
| ▲ Q2 FY2025 | May 12, 2025 | -$1.01 | $0.90 | +189.1% | — | — | — |
| ▼ Q1 FY2025 | Feb 28, 2025 | -$0.98 | -$0.99 | -1.0% | — | — | — |
| ▼ Q4 FY2024 | Nov 8, 2024 | -$0.90 | -$1.05 | -16.7% | — | — | — |
| ▲ Q3 FY2024 | Aug 9, 2024 | -$0.90 | -$0.81 | +10.0% | — | — | — |
| — Q2 FY2024 | May 10, 2024 | -$0.90 | -$0.90 | +0.0% | — | — | — |
| ▼ Q1 FY2024 | Feb 29, 2024 | -$0.82 | -$0.99 | -20.7% | $0.00B | — | — |
Q4 FY2025
Nov 7, 2025Miss
EPS Actual
-$0.99
EPS Est.
-$0.94
EPS Surpr.
-5.3%
Revenue
—
Q3 FY2025
Aug 8, 2025Beat
EPS Actual
-$0.86
EPS Est.
-$0.97
EPS Surpr.
+11.3%
Revenue
—
Q2 FY2025
May 12, 2025Beat
EPS Actual
$0.90
EPS Est.
-$1.01
EPS Surpr.
+189.1%
Revenue
—
Q1 FY2025
Feb 28, 2025Miss
EPS Actual
-$0.99
EPS Est.
-$0.98
EPS Surpr.
-1.0%
Revenue
—
Q4 FY2024
Nov 8, 2024Miss
EPS Actual
-$1.05
EPS Est.
-$0.90
EPS Surpr.
-16.7%
Revenue
—
Q3 FY2024
Aug 9, 2024Beat
EPS Actual
-$0.81
EPS Est.
-$0.90
EPS Surpr.
+10.0%
Revenue
—
Q2 FY2024
May 10, 2024
EPS Actual
-$0.90
EPS Est.
-$0.90
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2024
Feb 29, 2024Miss
EPS Actual
-$0.99
EPS Est.
-$0.82
EPS Surpr.
-20.7%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-1.17 | $-1.17 | $-1.17 | 1 |
| Q3 FY2026 | $-1.09 | $-1.09 | $-1.09 | 1 |
| Q2 FY2026 | $-1.06 | $-1.06 | $-1.06 | 1 |
| Q1 FY2026 | $-1.03 | $-1.03 | $-1.03 | 2 |
| Q4 FY2025 | $-1.11 | $-1.00 | $-0.93 | 5 |
| Q3 FY2025 | $-1.01 | $-0.95 | $-0.91 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q4 FY2025 | Nov 7, 2025 | -5.3% | $53.91 | $54.04 | +0.24% |
| ▲ Q3 FY2025 | Aug 8, 2025 | +11.3% | $50.45 | $50.46 | +0.02% |
| ▲ Q2 FY2025 | May 12, 2025 | +189.1% | $39.85 | $41.53 | +4.22% |
| ▼ Q1 FY2025 | Feb 28, 2025 | -1.0% | $47.75 | $49.12 | +2.87% |
| ▼ Q4 FY2024 | Nov 8, 2024 | -16.7% | $34.87 | $34.45 | -1.20% |
| ▲ Q3 FY2024 | Aug 9, 2024 | +10.0% | $24.93 | $24.74 | -0.76% |
| ▲ Q2 FY2024 | May 10, 2024 | +0.0% | $20.80 | $19.65 | -5.53% |
| ▼ Q1 FY2024 | Feb 29, 2024 | -20.7% | $27.23 | $26.99 | -0.88% |
Q4 FY2025+0.24%
Report Date
Nov 7, 2025
EPS Beat/Miss
-5.3%
Price Before
$53.91
Price After
$54.04
Q3 FY2025+0.02%
Report Date
Aug 8, 2025
EPS Beat/Miss
+11.3%
Price Before
$50.45
Price After
$50.46
Q2 FY2025+4.22%
Report Date
May 12, 2025
EPS Beat/Miss
+189.1%
Price Before
$39.85
Price After
$41.53
Q1 FY2025+2.87%
Report Date
Feb 28, 2025
EPS Beat/Miss
-1.0%
Price Before
$47.75
Price After
$49.12
Q4 FY2024-1.20%
Report Date
Nov 8, 2024
EPS Beat/Miss
-16.7%
Price Before
$34.87
Price After
$34.45
Q3 FY2024-0.76%
Report Date
Aug 9, 2024
EPS Beat/Miss
+10.0%
Price Before
$24.93
Price After
$24.74
Q2 FY2024-5.53%
Report Date
May 10, 2024
EPS Beat/Miss
+0.0%
Price Before
$20.80
Price After
$19.65
Q1 FY2024-0.88%
Report Date
Feb 29, 2024
EPS Beat/Miss
-20.7%
Price Before
$27.23
Price After
$26.99
Avg Beat Reaction-0.51%
Avg Miss Reaction+0.26%
Beat Rate4 / 8 quarters
Largest Move-5.53% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AKRO ends December
Akero Therapeutics, Inc. (AKRO) most recently reported earnings on November 7, 2025 for Q4 FY2025, posting EPS of $-0.99 — missing the analyst consensus of $-0.94 by -5.3%. The next AKRO earnings date is expected around September 1, 2026.
Each quarter, investors track AKRO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AKRO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AKRO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AKRO earnings · 5 questionsAkero Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. AKRO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AKRO historically reports after market close (AMC).
AKRO earnings datewhen is AKRO earningsAKRO next earnings datewhen does AKRO report earningsAKRO earnings calendar
▸ Source: FMP · Akero Therapeutics, Inc. SEC filings · US GAAP · Akero Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026